Innovative trial designs are practical solutions for improving the treatment of tuberculosis

Journal of Infectious Diseases

Volumn 205, Issue SUPPL. 2, 2012, Pages

  Phillips, Patrick P J ^a   Gillespie, Stephen H ^b   Boeree, Martin ^c   Heinrich, Norbert ^d   Aarnoutse, Rob ^c   McHugh, Tim ^e   Pletschette, Michel ^d   Lienhardt, Christian ^f   Hafner, Richard ^g   Mgone, Charles ^h   Zumla, Alimuddin ^e   Nunn, Andrew J ^a   Hoelscher, Michael ^d  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MUNICH   (Germany)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h European & Developing Countries Clinical Trials Partnership   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; RIBOSOME RNA; RIFAMPICIN;

ANALYSIS; ARTICLE; BACTERIUM CULTURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DESIGN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOLLOW UP; HUMAN; INTERIM ANALYSIS; MOLECULAR DIAGNOSIS; MULTI ARM MULTI STAGE DESIGN; MYCOBACTERIUM TUBERCULOSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; PATIENT SELECTION; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TIME FACTORS; TUBERCULOSIS;

EID: 84860385130     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis041     Document Type: Article

References (23)

1. Nunn AJ, Phillips PPJ, Gillespie SH. Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis 2008; 88:S85-92.
2. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12:128-38.
3. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for Isoniazid during Intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180:273-80.
4. Davies GR, Brindle R, Khoo SH, Aarons LJ. Use of nonlinear mixedeffects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrob Agents Chemother 2006; 50:3154-6.
5. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-40.
6. Nahid P, Saukkonen J, Mac Kenzie WR, et al. CDC/NIH workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med 2011; 184:972-9.
7. Lienhardt C, Raviglione MC, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise and prospects for the future. J Infect Dis 2012; 205(Suppl 2):S241-9.
8. Todd S. A 25-year review of sequential methodology in clinical studies. Stat Med 2007; 26:237-52.
9. Parmar MK, Barthel FM, Sydes M, et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 2008; 100:1204-14.
10. Royston P, Barthel F, Parmar M, Choodari-Oskooei B, Isham V. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit. Trials 2011; 12:81.
11. Sydes MR, Parmar MK, James ND, et al. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials 2009; 10:39.
12. Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 1989; 45:537-47.
13. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373:1183-9.
14. Desjardin LE, Perkins MD, Wolski K, et al. Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med 1999; 160: 203-10.
15. Honeyborne I, McHugh TD, Phillips PP, et al. Molecular Bacterial Load Assay, a Culture-Free Biomarker for Rapid and Accurate Quantification of Sputum Mycobacterium tuberculosis Bacillary Load during Treatment. J Clin Microbiol 2011; 49:3905-11.
16. Li L, Mahan CS, Palaci M, et al. Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy. J Clin Microbiol 2010; 48:46-51.
17. Hellyer TJ, DesJardin LE, Hehman GL, Cave MD, Eisenach KD. Quantitative analysis of mRNA as a marker for viability of Mycobacterium tuberculosis. J Clin Microbiol 1999; 37:290-5.
18. Gamboa F, Manterola JM, Lonca J, et al. Rapid detection of Mycobacterium tuberculosis in respiratory specimens, blood and other non-respiratory specimens by amplification of rRNA. Int J Tuberc Lung Dis 1997; 1:542-55.
19. Kosterink JG. Positron emission tomography in the diagnosis and treatment management of tuberculosis. Curr Pharm Des 2011; 17: 2875-80.
20. Holtz TH, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006; 144: 650-9.
21. Treweek S, Pitkethly M, Cook J, et al. Strategies to improve recruitment to randomised controlled trials. Cochrane Database Syst Rev 2010; (4): MR000013.
22. Ellenberg S, Fleming TR, DeMets DL. Data Monitoring Committees in Clinical Trials: A Practical Perspective. Wiley: Chichester, UK, 2002.
23. Yasinskaya Y, Sacks L. Models and approaches for anti-TB drug testing. Expert Rev Anti Infect Ther 2011; 9:823-31.